Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Reengineering a patient’s own immune system to hunt down and destroy cancer cells sounds like science fiction, but it’s not.

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

As community oncology evolves to deliver chimeric antigen receptor (CAR) T and bispecific therapies closer to home, support ...

The research team demonstrated that innate immune cells called Natural Killer (NK) cells that express CD8a on the cell ...

Pharmacists play a crucial role in managing treatment with chimeric antigen receptor T-cell therapy and bispecific antibodies, focusing on patient selection and side effects, explained Eileen Peng, ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

The study, which is the largest reported trial to date of CAR T therapy for solid tumors, evaluated CAR T cells engineered to target the tumor-associated antigen interleukin-13 receptor alpha 2 ...

Coadministration of CD19- and CD22-chimeric antigen receptor T-cell therapy may be a promising therapeutic strategy for patients with relapsed or refractory B-acute lymphoblastic leukemia. However, ...

Fig 1. Response to the combination of anti-BCMA and anti-CD19 chimeric antigen receptor T cells. (A) The rates of overall response, minor response, and no response. Patients with MRD status were ...